Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Global Sales of Hepatitis C Virus Market to Grow $12.8 billion by 2022 Says a New Report Available at MarketOptimizer.org
  • USA - English


News provided by

Market Optimizer

Sep 28, 2014, 06:30 ET

Share this article

Share toX

Share this article

Share toX

Market Research Report and Industry Analysis Reports
Market Research Report and Industry Analysis Reports

Dallas, TX (PRWEB) September 28, 2014 -- The Hepatitis C Virus Market generated approximately $4.2 billion from global sales in 2012. Over the next 10 years, this market is expected to grow to reach $12.8 billion, with major growth occurring in the main Hepatitis C Virus Markets, such the US.

Some of the main drivers of market growth are expected to be:

Launch of Interferon-Free Regimens Will Fundamentally Change the HCV Treatment Algorithm in the US, Japan, and Many European Countries

Post this
  • Introduction of interferon-free HCV regimens, which have an improved side effect profile compared with the first-generation direct-acting antiviral (DAA) and interferon-sparing HCV therapies
  • The arrival of fixed-dose combination therapies, which are expected to help simplify treatment
  • Increase in patient awareness of HCV through screening initiatives and public awareness campaigns
  • A paradigm shift toward the preventative treatment of HCV in most countries

The barriers limiting the growth of the market include:

  • Limited patient awareness regarding the threat of HCV
  • Concerns over decreasing healthcare spending as part of government austerity measures

Complete Report Details Available @ http://www.marketoptimizer.org/pharmapoint-hepatitis-c-virus-global-drug-forecast-and-market-analysis-to-2022-event-driven-update.html .

Key Questions Answered

  • How quickly, and to what extent, will interferon-sparing and all-oral regimens replace Incivek and Victrelis in the treatment algorithm?
  • What role, if any, will interferon-based therapies have in the HCV treatment landscape over the next decade?
  • Which novel HCV therapies will face adoption challenges in the market? What is the projected uptake of new drugs, such as Merck’s MK-5172/MK-8742, over the forecast period?
  • Will the reduced pill burden and increased convenience of fixed-dose, all-oral combination therapies lead to their widespread uptake?
  • How will pricing influence the use of next-generation DAAs?
  • Which HCV regimen(s) in development are physicians most excited about?

Key Findings

  • Patient awareness is anticipated to increase in response to government education and screening initiatives.
  • Interferon use is predicted to drastically decrease over the next 10 years.
  • The launch of next-generation, all-oral DAA regimens is expected to streamline the HCV treatment algorithm.
  • The approval of more-tolerable HCV therapies is likely to result in patients deciding to undergo treatment.
  • Fixed-dose combination therapies are expected to seize market share due to their reduced pill burden and convenience.

Order a Purchase Copy @ http://www.marketoptimizer.org/contacts/purchase?rname=10698 .
(This is a premium report priced at US$10995 for a single user License.)

Below Company Profiles include in Report:

  • Merck
  • Roche
  • Vertex
  • Janssen
  • Gilead
  • AbbVie
  • Bristol-Myers Squibb
  • Boehringer Ingelheim
  • Mitsubishi Tanabe Pharmaceutical Corporation
  • Achillion
  • Scynexis
  • Idenix
  • Presidio
  • Novartis

Pharma Giants Battle as New Entrants Leverage Interferon-Sparing and Interferon-Free HCV Regimens to Capture Market Share

Roche and Merck had been the HCV market leaders for the better part of two decades. The companies leveraged their interferon and ribavirin drugs to quickly capture market share. Roche’s and Merck’s commitment to innovation later resulted in the launch of peginterferon HCV therapies, which quickly overtook the market, but both companies fell behind in the race to develop the first DAA therapies for HCV. This enabled Vertex to establish itself as the leader in the US with the launch of Incivek (telaprevir) in 2011. Janssen was also able to capitalize on the demand for DAAs to become the front-runner in many European markets through the launch of Incivo (telaprevir). The arrival of interferon-sparing regimens, most notably Gilead’s Sovaldi (sofosbuvir) and Janssen’s Olysio (simeprevir), in late 2013 has resulted in the reduced uptake of the first-generation DAAs as patients wait for even better therapies on the horizon.

Companies Prioritize the Development of All-Oral HCV Regimens

The current HCV therapies have satisfactory efficacy, but they still require co-administration with peginterferon and ribavirin for the majority of patients. The shortcomings of the first-generation DAAs (Incivek and Victrelis [boceprevir]) and the first-to-market interferon-sparing (Sovaldi and Olysio) regimens have created an opportunity for the next-generation interferon-free therapies, especially in the US, Japan, and many European countries. GlobalData anticipates that more tolerable and convenient all-oral therapies will experience robust uptake in these markets.

AbbVie’s combination therapy (ABT-450/ombitasvir + dasabuvir) is expected to be among the first interferon-free HCV regimens to launch in several countries for GT1 patients. The regimen’s tolerability, efficacy in both treatment-naïve and treatment-experienced patients, and short duration of therapy are expected to result in it becoming a front-line therapy. GlobalData forecasts peak-year sales for the regimen of $2.2 billion in 2016. Other all-oral regimens, such as BMS’ daclatasvir/asunaprevir/BMS-791325 and Merck’s MK-5172/MK-8742, are also expected to seize market share from the interferon-sparing therapies, with peak-year sales of $1.0 billion in 2017 and $1.7 billion in 2019, respectively.

Explore more reports on Pharmaceuticals industry at http://www.marketoptimizer.org/category/life-sciences/pharmaceuticals .

About Us:
MarketOptimizer.org is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Ritesh Tiwari, Market Optimizer, http://www.marketoptimizer.org/, +1 (888) 391-5441, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.